switching between glp-1 agonists chart Schematic illustration of monoagonists, dual and triple Outcomes in GLP-1 RA-Experienced Patients
Description
Future research should focus on longitudinal dietary assessment, biomarker monitoring, and validation of standardized nutrition protocols for patients receiving GLP1-based obesity pharmacotherapy.
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are two gut hormones, defined incretins, responsible for the amplification of insulin secretion after oral glucose intake
Explore the mechanisms, clinical applications, and future opportunities of GLP-1 receptor agonists in drug development and disease management.
How retatrutide works: the first triple agonist targeting GIP, GLP-1, and glucagon receptors
